Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Loiasis
Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Phase 2 N=48 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
Old World Cutaneous Leishmaniasis
Primary: Safety: Overview of Adverse Events — 16; 7; 0; 0 Participants
Phase 2 N=92 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
Phase 2 N=154 Safety and Efficacy of IDA for Onchocerciasis
Onchocerciasis
Primary: Rates of Severe Adverse Events (SAEs) Across Study Arms — 0; 0; 0 Participants
Phase 3 N=375 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Cutaneous Leishmaniasis
Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001
Phase 3 N=399 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Cutaneous Leishmaniasis
Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants
N/A N=150 Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Skin Diseases
Primary: True Positive — 0 samples
Phase 3 N=118 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants
Phase 2 N=50 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Cutaneous Leishmaniasis
Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants
N/A N=17,108 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Lymphatic Filariasis · Soil Transmitted Helminth Infections
Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants
Phase 2 N=414 Sodium Stibogluconate Treatment of Leishmaniasis
Leishmaniasis
Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 3 N=437 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
Cutaneous Leishmaniasis
Primary: Complete Clinical Response — 85; 103; 86 participants
Phase 3 N=332 Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Cure Rate Against Strongyloides Stercoralis — 94.8; 99.4 percentage of participants
Phase 3 N=12,979 Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Onchocerciasis
Primary: Incidence and Severity of Treatment Emergent Adverse Events — 346; 79; 1199; 288 participants
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 2 N=288 L9LS MAb in Malian Adults
Plasmodium Falciparum Infection · Malaria
Primary: Number of Participants With Local Adverse Events (AEs) — 7; 1; 0; 0 Participants
Phase 2 N=4 Miltefosine to Treat Mucocutaneous Leishmaniasis
Mucosal Leishmaniasis · Cutaneous Leishmaniasis
Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants
Phase 3 N=74 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral Leishmaniosis · HIV-infection/Aids
Primary: Probability of Relapse-free Survival — 79; 71 percentage probability
Phase 4 N=104 Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon
Scabies · Households
Primary: Number of Participants With Clinical Cure — 20; 33 Participants